Condition
Any Stage of Lung Cancer (Any Histotype)|Any Stage of Malignant Pleural Mesothelioma|Any Stage of Any Thymic Malignancy
Estimated Enrollment: 3500
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Observational
Study Design Allocation: Observational Model: Cohort|Time Perspective: Prospective
Study ID Numbers: EORTC-1335-LCG-PBG
Study First Received: August 7, 2014
Last Updated: January 17, 2017
Estimated Primary Completion Date: January 2019
Primary Outcome Measures:
Number of patients with thoracic malignancy (lung cancer, MPM and thymic malignancies) screened and efficiently allocated to biomarker-driven clinical trials.|Number of patients for whom the description of the biomarkers and correlation to clinical/pathological characteristics can be performed.|Number of exploratory/future research projects developped
Sponsors and Collaborators:
European Organisation for Research and Treatment of Cancer – EORTC|European Thoracic Oncology Platform
Website Link: https://ClinicalTrials.gov/show/NCT02214134
